Skip to main content

Dilip Shanghvi displaces Mukesh Ambani as India’s richest person

Mumbai: Sun Pharmaceutical Industries Ltd founder Dilip S. Shanghvi on Wednesday overtook Reliance Industries Ltd’s Mukesh Ambani as India’s richest person, according to the Bloomberg Billionaires Index. Shanghvi has a net worth of $21.7 billion, while Ambani, who’s been India’s wealthiest man since the inception of the Bloomberg index in March 2012, has a $21.6 billion fortune. Shanghvi, a first generation entrepreneur, is also chairman and managing director of Sun Pharma Advanced Research Co Ltd, and chairman of the Shantilal Shanghvi Foundation. He holds a B.Com degree from Kolkata University. The Bloomberg Billionaires Index is a daily ranking. The index is a dynamic measure of the world’s wealthy based on changes in markets, the economy and Bloomberg reporting. Stakes in publicly traded companies are valued using the share’s most recent closing price. Valuations are converted to US dollars at current exchange rates. “It comes as no surprise to see an enterprising Gujarati like Shanghvi top the charts. A self-made man, with high business acumen, vision, and an eye to spot a hidden gem or opportunity instantly,” said Amar Ambani, head of research at India Infoline Finance Ltd.​ According to Bloomberg, the majority of Shanghvi’s wealth comes from his 60.8% stake in Sun Pharma. He also owns shares of Sun Pharma Advanced Research Co., Natco Pharma Ltd and Bio Light Israeli Life Sciences Investments Ltd. In April, Shanghvi, 60, announced an all-stock deal to buy troubled Ranbaxy Laboratories Ltd, hoping to turn it around and bring it under Sun Pharma’s fold. The $3.2 billion deal with Daiichi Sankyo Co. Ltd is the second largest deal ever in the Indian pharmaceutical sector. The acquisition, which is expected to close by end of this financial year, will make Sun Pharma the largest Indian generic drug maker and the fifth biggest in the world. Shares of Sun Pharmaceutical have surged 75.25% this fiscal year against 4.58% decline in Reliance Industries while the benchmark Sensex index gained 31.24%. Before concluding the Ranbaxy deal, Sun Pharma had made 13 acquisitions between the late 1990s and 2012, starting with the purchase in 1997 of Detroit-based Caraco Pharmaceutical Laboratories Ltd. Not all of these were easy. In 2010, it acquired a 66% stake in Israel-based Taro Pharmaceutical Industries Ltd after a four-year legal battle with its founders—the Levitt family—in a move that more than doubled its revenue in the US to $1.1 billion from $484 million.

Read more at:


Popular posts from this blog

Future of oil is bleak. By 2030, 95% of people may not own private cars which would wipe off the automobile industry

A futurist and clean energy expert, Toni Seba, has predicted that electric vehicles would destroy the global oil industry after a decade. By 2030, 95% of people won't own private cars which would wipe off the automobile industry, he says.

Boeing and JetBlue Airways have announced they would begin selling a hybrid-electric commuter aircraft by 2022. Planned by start-up Zunum Aero, the small plane would seat up to 12 passengers and reduce travel time and cost of trips under 1,600 km.


Can Herbalife 'Afresh' cause insomnia(sleeplessness) and heart problems?

Here is another "great" product from Herbalife. Marketed as an ENERGY drink mix. Few people know it contains Gurana seeds which have no active compound giving artificial energy other than caffeine. Afresh also contains additional caffeine

Ingredients of Herbalife Afresh Energy Drink Mix:
Maltodextrin, Orange Pekoe Extract, Guarana Seed Extract, Acidity Regulator - 330 and Caffeine Powder.

Side effect include insomnia, sleeplessness and heart problems, It is especially harmful for people with High blood pressure.

PPF interest rate cut to 7.9% but are other investment options better? Here's a comparison

The Public Provident Fund (PPF) will now offer 7.9% but experts say it is still a good option for investors. Given that consumer inflation is down to 3.65%, the real rate of return of the PPF is a healthy 4.25%. 

"This is quite impressive for an option that offers assured returns," says Amol Joshi, Founder, PlanRupee Investment Service. "Investors should continue to take advantage of this long-term tax-free product," he adds. 

Even if you compare the PPF rate with the 10-year government bond yield, the scheme is attractive. "The 10-year bond yield is a better benchmark for PPF than consumer inflation," says Manoj Nagpal, CEO, Outlook Asia Capital
Currently, the 10-year bond yield is around 6.8% and the PPF at 7.9% makes it for a premium of 110 basis points. "Historically, the average premium has been around 75 bps. So, the PPF investor is today earning a higher real return," says Nagpal. Even so, some investors may be feeling disappointed by the cu…